Navigation Links
Accumetrics Announces $16.5M in New Capital Financing

SAN DIEGO, Oct. 6 /PRNewswire/ -- Accumetrics, Inc., developer and marketer of the VerifyNow® System, the first rapid and easy-to-use diagnostic system for measuring an individual's response to multiple antiplatelet agents, announced today that it has completed a round of financing that will raise $16.5 million in new capital. The capital infusion, which will fully finance the company into 2011, came from the company's existing investors, including Arnerich Massena, BBT Fund/Apothecary Capital, Essex Woodlands Health Ventures, Kaiser Permanente Ventures and RiverVest Venture Partners.

Accumetrics' VerifyNow System helps physicians assess their patients' response to life-saving antiplatelet therapies, such as aspirin, Plavix®, Effient(TM) and GP IIb/IIIa inhibitors. Patients respond to antiplatelet medications differently; patients with impaired response may be at significantly greater risk for death, heart attack or stroke(1-4). The VerifyNow System helps physicians rapidly determine an individual patient's response to his or her therapy, without the usual time lag for laboratory analysis. Doctors use this information to ensure their patients are receiving the optimal treatment. Over 80 million people in the U.S. have heart disease(5), 50 million are on chronic aspirin therapy(6), and more than 25 million prescriptions are written annually for Plavix, the second largest selling drug worldwide(7).

"We have an outstanding group of investors who believe in our technology and our market opportunity and are encouraged by the execution of our 2009 plan. We look at 2010 as a breakthrough year for Accumetrics, and are pleased to be very well capitalized as we enter this important period in our history," said Timothy I. Still, President and CEO of Accumetrics.

Tony Arnerich, Accumetrics' Chairman of the Board and the largest shareholder in Accumetrics, stated, "This is a very effective management team, and we view the VerifyNow platform as a breakthrough technology in one of the most important remaining areas of cardio-diagnostics. We felt it was very important to ensure the financial stability necessary to allow this excellent team to execute on their ambitious business plan."

The capital will be funded in two closing transactions, with the first in 2009 and the second in 2010. Accumetrics reported that these proceeds will fund the completion of a number of key milestones planned for 2010 including expanded claims for existing products, new product development and continued expansion of its commercialization efforts both internationally and within the United States.

About Accumetrics (

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy to use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient) and clopidogrel (Plavix)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

    (1)  Patti, G. et al. J Am Coll Cardiol. 2008; 52:1128-33.
    (2)  Marcucci, R. et al. Circulation. 2009;119(2):237-42.
    (3)  Cuissett, T. et al. Am J Cardiol;2008 Jun 15;101(12):1700-3.
    (4)  Price, MJ. et al. Eur Heart J. 2008 Apr;29(8):992-1000.
    (5)  American Heart Association and American Stroke Association. 2008.
    (6)  Pignone,  M. et al.  Am J Prev Med 2007;32(5):403-407.
    (7)  WSJ. January 26, 2009.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of sanofi-aventis. Effient is a trademark of Lilly-Daiichi Sankyo.

    Megan Rusnack
    Lippert/Heilshorn & Associates

    Timothy I. Still
    President and CEO

SOURCE Accumetrics, Inc.

SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
2. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
3. Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... recently ... of Eyeglasses . , Millions of individuals in the United States and Canada ... become a way to both correct vision and make a fashion statement. Even celebrities ...
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
Breaking Medicine News(10 mins):